
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934**

Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐

Check the appropriate box:

- ☐ Preliminary Proxy Statement
- ☐ **Confidential, for Use of the Commission Only** (as permitted by Rule 14a-6(e)(2))
- ☐ Definitive Proxy Statement
- ☒ Definitive Additional Materials
- ☐ Soliciting Material Pursuant to §240.14a-12



IGC Pharma, Inc.

(Exact name of registrant as specified in its charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- ☒ No fee required.
- ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
- ☐ Fee paid previously with preliminary materials.
- ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
-
-

Your **Vote** Counts!

IGC PHARMA, INC.
2026 Annual Meeting
Vote by December 01, 2026
11:59 PM ET



You invested in IGC PHARMA, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on December 02, 2026.**

Get informed before you vote

View the Form 10-K, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to November 16, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit **www.ProxyVote.com**

Control #

Smartphone users

Point your camera here and
vote without entering a
control number



Vote in Person at the Meeting*

December 02, 2026
11:00 AM EST

10224 Falls Road, Potomac, Maryland 20854

*If you choose to vote these shares in person at the meeting, you must request a "legal proxy." To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

IGC PHARMA, INC.
2026 Annual Meeting
Vote by December 01, 2026
11:59 PM ET

Voting Items		Board Recommends
1	To elect Ms. Claudia Grimaldi to the Company's Board of Directors to serve as a Class A director until the 2029 Annual Meeting of Stockholders, until such directors successor shall be duly elected and qualified, or until such directors earlier death, resignation, or removal from office;	✔ For
2	To approve an amendment to Section 4.1 of the Company's 2018 Omnibus Incentive Plan to change the annual share reserve adjustment date from April 1 to January 1 of each year, effective January 1, 2027;	✔ For
3	To approve an amendment to Section 4.1 of the Company's 2018 Omnibus Incentive Plan to increase the annual share reserve percentage from fifteen percent (15%) to twenty percent (20%), effective January 1, 2027;	✔ For
4	To approve the grant of 5,000,000 shares of common stock, governed by the Company's 2018 Omnibus Incentive Plan, to be granted from time to time to the Company's current and new employees, officers, advisors, directors, and consultants by the Board of Directors, pursuant to certain metrics including performance, vesting, and incentive as set by the Board of Directors and or the CEO;	✔ For
5	To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers as disclosed pursuant to the SEC's compensation disclosure rules (which disclosure includes the compensation tables, and the narrative disclosures that accompany the compensation tables) (the Say-on-Pay Proposal);	✔ For
6	To ratify the appointment of Manohar Chowdhry & Associates, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026;	✔ For
7	To act upon such other matters as may properly come before the Annual Meeting, including any proposal to adjourn or postpone the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies (the "Adjournment Proposal").	✔ For